[HTML][HTML] COVID-19 and multiorgan failure: A narrative review on potential mechanisms
The outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) in
December 2019 form Wuhan, China leads to coronavirus disease 2019 (COVID-19) …
December 2019 form Wuhan, China leads to coronavirus disease 2019 (COVID-19) …
Inflammatory cytokine: IL-17A signaling pathway in patients present with COVID-19 and current treatment strategy
T Shibabaw - Journal of inflammation research, 2020 - Taylor & Francis
Abstract Coronavirus disease 2019 (COVID-19) is a globally communicable public health
disease caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV-2) …
disease caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV-2) …
IL-6 and IL-10 are associated with disease severity and higher comorbidity in adults with COVID-19
RL Luporini, JMA Rodolpho, LT Kubota, ACBM Martin… - Cytokine, 2021 - Elsevier
Aim COVID-19 pandemic has caused extensive burden on public life and health care
worldwide. This study aimed to assess circulating levels of inflammatory cytokines in adult …
worldwide. This study aimed to assess circulating levels of inflammatory cytokines in adult …
[HTML][HTML] Molecular mechanisms involved in the positive effects of physical activity on coping with COVID-19
Purpose Physical activity (PA) represents the first line of defence against diseases
characterised by increased inflammation status, such as metabolic and infectious diseases …
characterised by increased inflammation status, such as metabolic and infectious diseases …
[HTML][HTML] SARS-Cov2 acute and post-active infection in the context of autoimmune and chronic inflammatory diseases
R Larionova, K Byvaltsev, О Kravtsova, E Takha… - Journal of Translational …, 2022 - Elsevier
The clinical and immunological spectrum of acute and post-active COVID-19 syndrome
overlaps with criteria used to characterize autoimmune diseases such as rheumatoid …
overlaps with criteria used to characterize autoimmune diseases such as rheumatoid …
[HTML][HTML] Serum lipid mediator profiles in COVID-19 patients and lung disease severity: a pilot study
P Irún, R Gracia, E Piazuelo, J Pardo, E Morte… - Scientific Reports, 2023 - nature.com
Abstract Coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 infection is highly
heterogeneous, ranging from asymptomatic to severe and fatal cases. COVID-19 has been …
heterogeneous, ranging from asymptomatic to severe and fatal cases. COVID-19 has been …
[HTML][HTML] Interleukin-17A (IL-17A): A silent amplifier of COVID-19
One of the hallmarks of COVID-19 is the cytokine storm that provokes primarily pneumonia
followed by systemic inflammation. Emerging evidence has identified a potential link …
followed by systemic inflammation. Emerging evidence has identified a potential link …
Folic acid: A potential inhibitor against SARS-CoV-2 nucleocapsid protein
YM Chen, JL Wei, RS Qin, JP Hou, GC Zang… - Pharmaceutical …, 2022 - Taylor & Francis
Context Coronavirus disease 2019 is a global pandemic. Studies suggest that folic acid has
antiviral effects. Molecular docking shown that folic acid can act on SARS-CoV-2 …
antiviral effects. Molecular docking shown that folic acid can act on SARS-CoV-2 …
[HTML][HTML] A comparative study of the plasma chemokine profile in COVID-19 patients infected with different SARS-CoV-2 variants
ZR Korobova, NA Arsentieva, NE Liubimova… - International Journal of …, 2022 - mdpi.com
Background. Infection caused by SARS-CoV-2 mostly affects the upper and lower
respiratory tracts and causes symptoms ranging from the common cold to pneumonia with …
respiratory tracts and causes symptoms ranging from the common cold to pneumonia with …
The effect of higher-intensity dosing of anticoagulation on the clinical outcomes in hospitalized patients with COVID-19: A meta-analysis of randomized controlled trials
Objective We aimed to perform a meta-analysis to summarize the overall evidence from
randomized controlled trials related to higher-intensity anticoagulation in hospitalized …
randomized controlled trials related to higher-intensity anticoagulation in hospitalized …